Zogenix drops 10% after competitor gets Priority Review Shares of Zogenix (ZGNX) are moving lower after Purdue Pharma announced earlier today that the FDA has granted Priority Review designation for its once-daily, single-entity hydrocodone bitartrate tablet. The investigational pain medication was formulated to incorporate abuse-deterrent properties designed to make the product more difficult to manipulate for the purpose of misuse or abuse, Purdue stated. Shares of Zogenix, which has a competing pain killer drug called Zohydro ER without abuse-deterrent properties, are down 10%, or 22c, to $1.91 in afternoon trading.
News For ZGNX From The Last 14 Days
Check below for free stories on ZGNX the last two weeks.